Since DLX3 mutation (Q178R) could increase bone formation by preventing cell senescence even though with decreased osteogenic potential in vitro, we further generated transgenic mice expressing DLX3 mutation (Q178R) (named as DLX3 (Q178R)-Tg mice) to examine whether this novel mutation could protect against natural aging-mediated bone loss or osteopenia in vivo. The gene discussed is DLX3; the disease is Osteopenia.